Qiagen N.V. $QGEN Shares Sold by Earnest Partners LLC

Key Points

• Earnest Partners LLC has reduced its stake in Qiagen N.V. by 4.9%, selling 195,817 shares and now owning 3,806,672 shares valued at approximately $152.8 million.
• Despite the stake reduction, other large investors like Wellington Management Group and Deutsche Bank AG increased their holdings by 12.2% and 57.5% respectively during the same quarter.
• Qiagen recently reported earnings of $0.60 per share, meeting consensus estimates, and announced a dividend payout of $0.25 with a yield of 52.0% as of the last payment date.

Earnest Partners LLC lowered its stake in shares of Qiagen N.V. (NYSE:QGEN - Free Report) by 4.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,806,672 shares of the company's stock after selling 195,817 shares during the quarter. Earnest Partners LLC owned 1.71% of Qiagen worth $152,838,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the stock. Wellington Management Group LLP increased its position in shares of Qiagen by 12.2% during the first quarter. Wellington Management Group LLP now owns 24,438,441 shares of the company's stock worth $972,191,000 after acquiring an additional 2,656,136 shares during the period. Deutsche Bank AG increased its position in shares of Qiagen by 57.5% during the first quarter. Deutsche Bank AG now owns 4,491,131 shares of the company's stock worth $180,319,000 after acquiring an additional 1,639,621 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Qiagen by 3,030.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,470,728 shares of the company's stock worth $179,501,000 after acquiring an additional 4,327,934 shares during the period. Allspring Global Investments Holdings LLC increased its position in shares of Qiagen by 4.7% during the first quarter. Allspring Global Investments Holdings LLC now owns 2,445,641 shares of the company's stock worth $96,605,000 after acquiring an additional 109,481 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Qiagen during the fourth quarter worth $95,746,000. Hedge funds and other institutional investors own 70.00% of the company's stock.

Qiagen Price Performance

Shares of QGEN opened at $48.89 on Wednesday. Qiagen N.V. has a fifty-two week low of $37.63 and a fifty-two week high of $51.88. The company has a market capitalization of $10.87 billion, a price-to-earnings ratio of 28.88, a price-to-earnings-growth ratio of 2.57 and a beta of 0.64. The firm has a 50-day simple moving average of $48.69 and a 200-day simple moving average of $43.99. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61.

Qiagen (NYSE:QGEN - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, hitting the consensus estimate of $0.60. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The business had revenue of $533.54 million during the quarter, compared to the consensus estimate of $523.97 million. During the same quarter in the prior year, the firm earned $0.55 earnings per share. The business's quarterly revenue was up 7.7% compared to the same quarter last year. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, equities research analysts anticipate that Qiagen N.V. will post 2.26 earnings per share for the current year.

Qiagen Announces Dividend

The company also recently disclosed a dividend, which was paid on Thursday, July 10th. Investors of record on Thursday, July 3rd were given a $0.25 dividend. The ex-dividend date was Wednesday, July 2nd. This represents a yield of 52.0%. Qiagen's dividend payout ratio (DPR) is presently 14.79%.

Analysts Set New Price Targets

QGEN has been the topic of a number of recent research reports. Bank of America upped their price objective on Qiagen from $50.00 to $53.00 and gave the stock a "buy" rating in a research report on Thursday, June 26th. UBS Group increased their target price on Qiagen from $48.00 to $50.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Wall Street Zen lowered Qiagen from a "strong-buy" rating to a "buy" rating in a report on Monday, August 11th. Barclays assumed coverage on Qiagen in a report on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 target price on the stock. Finally, Cowen reissued a "hold" rating on shares of Qiagen in a report on Thursday, August 7th. Three investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $49.69.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NYSE:QGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.